EPIX nets South Korean approval of Vasovist
EPIX Pharmaceuticals has received marketing approval for its blood pool magnetic resonance angiography agent, Vasovist.
“We are pleased to announce the approval of Vasovist [gadofosveset trisodium] in South Korea, which is the 34th country outside the United States where this agent has been approved for marketing,” said Michael G. Kauffman, MD, PhD, CEO of EPIX.
“We remain hopeful for approval of Vasovist in the United States by the end of 2008 and, as previously announced, have recently resubmitted a new drug application for Vasovist to the FDA,” Kauffman added.
“We are pleased to announce the approval of Vasovist [gadofosveset trisodium] in South Korea, which is the 34th country outside the United States where this agent has been approved for marketing,” said Michael G. Kauffman, MD, PhD, CEO of EPIX.
“We remain hopeful for approval of Vasovist in the United States by the end of 2008 and, as previously announced, have recently resubmitted a new drug application for Vasovist to the FDA,” Kauffman added.